R21
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 62
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.570
- ANGIOGENESIS+0.420
- INTERFERON_ALPHA_RESPONSE+0.220
- CHOLESTEROL_HOMEOSTASIS+0.200
- E2F_TARGETS+0.190
- MYC_TARGETS_V1+0.180
- WNT_BETA_CATENIN_SIGNALING+0.170
- ADIPOGENESIS+0.160
- APICAL_SURFACE+0.160
- UNFOLDED_PROTEIN_RESPONSE+0.140
Top 10 suppressed
- PROTEIN_SECRETION-0.390
- ALLOGRAFT_REJECTION-0.360
- IL6_JAK_STAT3_SIGNALING-0.330
- KRAS_SIGNALING_UP-0.330
- ANDROGEN_RESPONSE-0.280
- UV_RESPONSE_DN-0.250
- COMPLEMENT-0.220
- HEME_METABOLISM-0.200
- MITOTIC_SPINDLE-0.200
- TNFA_SIGNALING_VIA_NFKB-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_4D9DD103 | Med | Medulloblastoma | 0.735 |
| 2 | 06114a88-396c-4815-8949-910e46345e47 | — | — | 0.715 |
| 3 | SRR12475170 | — | — | 0.713 |
| 4 | SJEPD032_D.RNA-Seq | EPN | Supratentorial EPN | 0.710 |
| 5 | BS_K3ER45RV | Med | Medulloblastoma | 0.710 |
| 6 | 689c3b5e-8bff-45d0-8165-b4b0e6dbf910 | — | — | 0.695 |
| 7 | 43c87798-5762-42c1-b7d8-47fc126fc2d3 | — | — | 0.691 |
| 8 | SRR12475106 | — | — | 0.687 |
| 9 | R1 | — | — | 0.682 |
| 10 | AUR-AF95-TTM1-A-1-1-R-A742-41 | — | E | 0.680 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.570 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.220 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.180 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.160 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.140 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.110 | Remibrutinib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |